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Abstract
Introduction The presence of monocyte and macrophage cells
in growing breast tumors, and the positive relationship between
the degree of immune cell infiltration and tumor growth, suggest
a possible paracrine growth regulatory function of immune cells
in breast cancer.
Method To better understand the interaction between
monocytes and breast cancer cells, in vitro matrix
metalloproteinase and tissue inhibitor of metalloproteinase
activity was assessed from the THP-1 myeloid cell line in
response to conditioned media from two breast cancer cell
lines, MCF-7 and MDA-MB-231.
Results Enzymography and immunoblotting revealed increased
MMP-2 as well as increased levels of TIMP-1 and TIMP-2.
Furthermore, a significant increase in the invasive potential of
MCF-7 and MDA-MB-231 cells was noted in response to THP-
1 cell-conditioned media.
Conclusion These data demonstrate that monocyte cells in the
breast tumor microenvironment play an important role in the
modulation of MMPs, which may have a significant effect on the
control of tumor growth and metastatic spread.
Introduction
There is a growing body of evidence to suggest that the tumor
microenvironment is immunosuppressive [1,2]. This is perhaps
as a result of selection for such an environment, which is a
process recently termed immunoediting [3]. The growth of
solid tumors has been likened to an aberration of the normal
process of wound healing and, in consequence, immune cells
may inadvertently aid tumor growth. The tumor microenviron-
ment often contains a number of migratory haematopoietic
cells that play pivotal roles in the progression and metastasis
of tumors [4-8]. Monocyte and macrophage cells are promi-
nent in the inflammatory infiltrate of tumors, often in consider-
able numbers [9-12], and it has been suggested that the
presence of these cells may independently influence the met-
astatic potential of certain tumors [13].
The clinical significance of the mononuclear infiltrate that is
often seen in breast cancer has remained the subject of con-
tinuous debate. In invasive breast carcinoma, the neoplastic
cell population is often outnumbered by stromal cells such as
tumor-associated macrophages (TAMs), which can comprise
as much as 80% of the entire tumor-associated leukocyte
(TAL) population [14], and more than 50% of the total tumor
mass [15]. It appears that TAMs are actually required for the
tumor to survive [16-19]. Other studies have also reported an
overwhelming predominance of TAMs within the TAL popula-
tion of both primary [12,20,21] and metastatic [22] breast car-
cinoma. Moreover, positive relationships between the
presence of macrophages and lymph node metastasis [23], c-
erbB2 [24], and increased expression of urokinase plasmino-
gen activator (uPA) [25] in breast cancer have been reported.
The majority of studies that have attempted to correlate mac-
rophage content with tumor severity have noted higher num-
bers of macrophages in conjunction with increasing tumor
malignancy potential. Among the stromal cells, the presence ofR661
BSA = bovine serum albumin; CM = conditioned media; ECM = extracellular matrix; FBS = fetal bovine serum; HRP = horse radish peroxidase; MMP 
= matrix metalloproteinase; TAL = tumor-associated leukocyte; TAM = tumor-associated macrophage; TIMP = tissue-inhibitor of matrix metallopro-
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tumors, indicating a relation between macrophages and the
degree of tumor cell differentiation [26-28]. These data are
particularly compelling for breast, prostate, ovarian and cervi-
cal cancers. There is clinical data correlating a poor prognosis
with the extent of macrophage infiltrate in breast cancer
patients [26] as well as the differential cytotoxicity of macro-
phages from regressing and progressing tumors [29]. Mono-
cytes represent precursor cells that serve as a source for the
constant renewal of tissue macrophages on demand as well
as in steady-state conditions. It is thought that monocytes in
the peripheral circulation are recruited to the tumor site [30] by
the release of chemotactic cytokines, and once recruited, the
monocytes differentiate to become TAMs.
Matrix metalloproteinases (MMPs) comprise a family of zinc-
containing endopeptidases that share structural domains and
have the capacity to degrade extracellular matrix (ECM) com-
ponents as well as to alter biological functions of ECM macro-
molecules [31]. The specific proteolytic targets of MMPs may
include many other proteases, protease inhibitors, clotting fac-
tors, chemotactic molecules, latent growth factors, growth fac-
tor binding proteins, cell surface receptors, as well as cell-cell
and cell-matrix adhesion molecules. Under physiological con-
ditions, the activity of MMPs is tightly regulated to prevent
excessive proteolytic activity and tissue destruction. Important
sources of MMPs are immune cells, which utilize these
enzymes to mediate extravasation into tissues during inflam-
mation. Although initially it was assumed that the tumor cell
was the origin of MMPs found in this environment, in situ
hybridization techniques have shown that while some MMPs
are expressed by tumor cells, MMPs are predominantly pro-
duced by adjacent host stromal and inflammatory cells in
response to factors released by tumors [32,33]. The tumor cell
MMPs may contribute to the invasive growth of the tumor while
the stromal elements contribute to the remodelling process
and the desmoplastic reaction that occurs in the tissue adja-
cent to the tumor [34].
MMPs produced by monocyte and macrophage cells, which
have been implicated in tumor cell invasion and metastasis,
may be enhanced by soluble factors from breast cancer cells.
While tumor cells have been extensively studied, the roles of
monocytes in the tumor microenvironment have not been well
characterized. In an attempt to further understand the roles of
monocytes in the tumor microenvironment, in vitro MMP and
tissue inhibitor of metalloproteinase (TIMP) protein levels and
enzymatic activity from THP-1 monocyte cells were assessed
in response to the breast cancer cell lines MCF-7 and MDA-
MB-231. An assessment of the invasive potential of these
breast cancer cell lines in response to the monocyte cells was
also conducted. Our results indicate that monocytes act as
important regulators of ECM breakdown during tumor invasion
and metastasis as a result of their ability to regulate MMP and
TIMP production following their migration to the tumor site.
Therefore, the basic mechanisms that regulate monocyte
recruitment from the circulation into a tumor site and their pro-
duction of MMPs and TIMPs are likely to be significant to
breast cancer research.
Materials and methods
Cell lines and cell culture
The monocyte cell line THP-1, the estrogen receptor positive
human breast cancer cell line MCF-7 and the estrogen recep-
tor negative breast cancer cell line MDA-MB-231 were
obtained from the American Type Culture Collection (Manas-
sas, VA, USA). All cell lines were cultured under standard tis-
sue culture conditions and tested negative for mycoplasma
contamination. These cell lines were maintained in RPMI 1640
medium (Gibco, Grand Island, NY, USA), supplemented with
10% w/v fetal bovine serum (FBS) (Gibco), 1 mM sodium
pyruvate, penicillin (100 units/ml) and streptomycin (100
units/ml) (Gibco) in a 5% CO2 incubator at 37°C. When
experimental conditions called for the use of phenol red-free
and serum-free media, the same RPMI medium was used as
above but without the phenol red and FBS. The cells were only
used a maximum of 15 passages and cells were grown to 80%
confluence prior to experimentation. All media and reagents
contained less than 0.06 endotoxin units/ml, confirmed by
testing in our laboratory using the Limulus Amebocyte Lysate
gel clot assay (Cambrex, East Rutherford, NJ, USA).
Collection of conditioned media
Cultured cells were washed three times with phenol red-free,
serum-free RPMI and incubated in this media for 48 h. Follow-
ing incubation, the cells were harvested, the recovered cell
number determined, and cell viability was assessed at the end
of each culture period by Trypan Blue exclusion. Samples of
tumor cell-derived conditioned media (CM) were collected
and centrifuged to remove cell debris. Harvested CM was con-
centrated using the Amicon Ultra-4 centrifugal filter units with
a nominal molecular weight limit of 10 kDa (Millipore, Bedford,
MA, USA). The CM was immediately frozen at -80°C until enzy-
mography or immunoblotting was performed.
Treatment of THP-1 cells with conditioned media
For CM studies, THP-1 cells were grown to subconfluency
(80% to 85%) in serum-supplemented media. The cells were
then pelleted and washed three times in phenol red-free and
serum-free RPMI before resuspension in this same media.
Prior to experimentation, the concentration of the THP-1 cells
was adjusted to 5 × 105 cells/ml by suspension in RPMI and
the cells were seeded into six-well, flat bottom plates. The total
volume of each well was 2.5 ml, with cells exposed to increas-
ing volumes of MCF-7 and MDA-MB-231 breast cancer cell
CM or incubated with control volumes of concentrated serum-
free media for 48 h. After the 48 h incubation time, cells and
debris were removed from the THP-1 supernatant by centrifu-
gation. Following incubation, the recovered cell number was
determined and cell viability established using Trypan Blue
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THP-1 cells with CM did not reduce the viability of the THP-1
cells.
Western blotting
The CM protein levels were quantified using a protein assay
(Bio-Rad, Hercules, CA, USA) and the results were compared
with a standard curve of BSA concentrations. The protein con-
centrations were used to normalize the amount of CM loaded
onto the gel; thus, the total protein loaded was equivalent in
each lane. Loading buffer (5% w/v SDS, 0.225 M Tris-Cl pH
6.8, 50% w/v glycerol, 0.05% w/v bromophenol blue, 0.25 M
dithiothreitol) was added to the CM and the mixture was dena-
tured by boiling for 5 minutes. Samples were loaded onto a
10% SDS polyacrylamide gel with 10 µl of a wide-range
colored protein molecular weight marker (Invitrogen, Carlsbad,
CA, USA) also loaded onto the gel. The proteins were subse-
quently transferred from the gel onto a nitrocellulose mem-
brane (Amersham Biosciences, Piscataway, NJ, USA). The
membrane was incubated with mouse monoclonal anti-MMP-
2 antibodies diluted 1:100 (Oncogene, Cambridge, MA,
USA), and mouse monoclonal anti-TIMP-2, anti-TIMP-2 and
anti-uPA antibodies diluted 1:400 (Oncogene). The mem-
brane was subsequently incubated with mouse anti-rabbit IgG
antibodies conjugated to horseradish peroxidase (HRP) or
goat anti-mouse IgG antibodies HRP diluted 1:5000 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). ECL chemilumi-
nescent detection (Amersham Biosciences) was used to visu-
alize the proteins.
Enzymography
Aliquots of CM were mixed with sample buffer (0.5 M Tris-HCl
pH 6.8, 10% w/v glycerol, 10% w/v SDS, and 0.1% w/v
bromophenol blue) and were subjected to electrophoresis on
a 10% SDS polyacrylamide gel containing 1 mg/ml gelatin
(Sigma, St. Louis, MO, USA) or 1 mg/ml casein (Sigma). After
electrophoresis, the gel was washed in 2.7% (v/v) Triton X-
100 for 1 h at 37°C. The gels were then incubated in a devel-
oping buffer (50 mM Tris Base, 40 mM 6N HCl, 200 mM NaCl,
5 mM CaCl2·H2O, 0.02% v/v Brij 35) for 15 minutes at room
temperature followed by an overnight incubation on a shaker
at 37°C in the same buffer to allow digestion of the substrate.
After digestion, the gels were rinsed briefly with deionized
water and stained with 0.5% (w/v) Coomassie Brilliant Blue R-
250 in 40% (v/v) ethanol and 10% (v/v) acetic acid for 1 h, fol-
lowed by destaining in a mixture of 30% (v/v) ethanol and 10%
(v/v) acetic acid. MMP proteolytic bands were identified by
examining unstained regions on the substrate-stained back-
ground; intact protein substrate stained blue, leaving enzyme
degraded bands transparent.
Reverse enzymography
Protein standardized samples of CM were resolved in 10%
SDS-PAGE containing 1 mg/ml gelatin (Sigma) and 1.5 µg/ml
MMP-9 (Sigma). After gel electrophoresis, the gels were
treated in the same manner as described for enzymography.
For the reverse zymogram, the stained areas of the gel indicate
enzymatic activity corresponding to the TIMP at that molecular
weight.
Motility and invasion assays
Cell motility was assessed using 24-well Matrigel Insert
Chambers (Becton Dickinson Labware, Franklin Lakes, NJ,
USA) with polycarbonate filters containing 8 µm pores coated
with growth factor reduced matrigel matrix (50 µg/filter). MCF-
7 and MDA-MB-231 cells were seeded at 5 × 104 cells/well
in the upper compartment of each invasion chamber. The
lower chambers contained serum-free media, serum-free
media containing 10% v/v FBS, as well as THP-1 CM, 5 × 104
and 10 × 104 MCF-7, MDA-MB-231 and THP-1 cells per
chamber. After 48 h, the top surface of the membrane was
gently scrubbed with a cotton bud and cells on the undersur-
face were fixed and stained with the DiffQuick staining kit
(Baxter, McGaw Park, Il, USA). The number of cells that had
migrated to the undersurface of the filters was counted in five
separate high-powered fields for each membrane. Values from
the separate experiments containing all conditions were aver-
aged and plotted on a bar graph ± their corresponding stand-
ard error.
Statistical analysis of the data
All experiments were repeated a minimum of three times and
representative results are shown. Student's t-test was used to
compare results from the treated cells with the results from
untreated control cells. Data are expressed as the mean ±
standard error of the mean. Results were considered statisti-
cally significant at p < 0.05.
Results
Induction of MMP activity from THP-1 monocytes
MCF-7 (Fig. 1a) and MDA-MB-231 (Fig. 2a) CM elicited
enhanced MMP-2 activity by THP-1 monocytes, as measured
by gelatin zymography, when compared to either unstimulated
controls or to the levels of the enzyme in the CM alone. Distinct
gelatinolytic bands were observed at calculated Mr 72,000,
and 92,000, corresponding to the latent 72 kDa type IV colla-
genase (MMP-2), and the latent form of 92 kDa type IV colla-
genase (MMP-9), respectively. At the highest concentration of
CM (300 µl) the enzymatic effect was the greatest. This coin-
cided with an increase in expression of MMP-2 (Figs 1b and
2b) protein levels produced by the monocyte cells as deter-
mined by immunoblot analysis. In addition, the presence of
casein-degrading MMPs was analysed by enzymography,
although there were no appreciable levels of MMP-1 or MMP-
7 produced. Western blot analysis confirmed this absence of
MMP-7 and, furthermore, the basal level MMP-9 and uPA pro-
duced by the monocyte cells was not changed upon exposure
to the breast cancer CM (results not shown).
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In addition to the contribution by MMPs, the degree of connec-
tive tissue destruction is also influenced by TIMPs. Reverse
enzymography using MMP-9 as the degrading source
revealed TIMP-1 and TIMP-2 activity (Figs 1c and 2c) at Mr
28,000 and 21,000, respectively. There was no difference in
the level of monocyte TIMP-1 or TIMP-2 inhibition between the
control and MCF-7 CM treated cells. Upon exposure to the
MDA-MB-231 CM, however, there was an increased level of
TIMP-2 inhibition (Fig. 2c). In order to compare the inhibitory
activity of TIMP-1 and TIMP-2 with the protein levels, immuno-
blot analysis was performed on the samples at the 300 µl opti-
mal concentration. The THP-1 monocytes produced
enhanced TIMP-1 (Fig. 3a,b) and TIMP-2 (Fig. 3c,d) protein
levels; thus a small increase in TIMP-1 expression as well as a
more substantial increase in TIMP-2 was observed.
Motility and invasive potential of MCF-7 and MDA-MB-
231 cells in response to monocytes
The previous results, and our interest in the ability of mono-
cytes to degrade the ECM, raised the question of whether or
not monocytes increase the invasive potential of breast cancer
cells. The presence of THP-1 CM led to a significant increase
(p < 0.05) in MCF-7 (Fig. 4a) cell invasion in comparison to the
serum-free media control. The presence of 5 × 104 THP-1
cells in the lower chamber also led to a significant increase (p
< 0.05) in the number of MCF-7 (Fig. 4a) and MDA-MB-231
(Fig. 4b) cells that invaded through the matrigel membrane.
The invasive potential of the breast cancer cells was main-
tained, however, as the concentration of the monocyte cells
was doubled.
Figure 1
The effects of MCF-7 breast adenocarcinoma CM on MMP and TIMP activity from THP-1 monocytes. (a) Gelatin zymogram and (b) MMP-2 immu-
noblot showing the upregulation of monocyte MMP-2 after exposure to MCF-7 CM, and (c) a reverse zymogram to show that the activity of mono-
cyte TIMP-1 and -2 remained the same upon treatment. Lanes 1, 4, and 7 contain CM from THP-1 cells in serum-free media grown in the presence 
of 100 µl, 200 µl and 300 µl concentrated MCF-7 CM, respectively. Lanes 2, 5, and 8 contain CM from THP-1 cells in serum-free media grown in 
the presence of 100 µl, 200 µl and 300 µl concentrated serum-free media, respectively. Lanes 3, 6, and 9 contain serum-free media with 100 µl, 
200 µl and 300 µl, respectively, of MCF-7 CM in the absence of THP-1 cells. These figures are representative of three independent experiments car-
ried out in duplicate, each of which demonstrates similar results.
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The expression of components of the matrix degrading pro-
tease system by tumor stromal cells indicates that the tumor
stroma does not merely play a passive role in cancer progres-
sion. Rather, it may in fact actively participate in the process of
cancer invasion. We propose that it is the mixed population of
cancer cells and recruited stromal cells that produce the
matrix degrading protease components in order to facilitate
the destruction of the surrounding normal tissue, which allows
for malignant cell invasion. Our present data may partially
explain why MMPs are often predominantly expressed by the
stromal cells that surround invasive neoplastic cells. Specifi-
cally, monocytes may play an important role in tumor invasion
and metastasis through their MMP proteolytic activity.
MMPs are usually expressed and secreted by cells as inactive
enzymes, and further proteolytic processing is necessary to
convert them into their active forms. The degradation of the
ECM, especially basement membrane type IV collagen, is con-
sidered a key event for tumor cell invasion and metastasis.
Specifically in colorectal cancer, MMP-9 is derived principally
from stromal monocytes [35,36] and a high level of MMP-9 in
tumor versus paired normal mucosa is an independent predic-
tor of poor prognosis [37]. Moreover, there is a connection
between the expression of TIMP-2 and MMP-2 under many
physiological and pathological conditions, suggesting that
TIMP-2 regulates MMP-2 activity [38,39]. Furthermore, TIMP-
1 and TIMP-2 over-expression has been associated with
malignant breast tumor behaviour in vivo [40,41]. Immunohis-
tochemical studies have indicated that MMP-2 is highly
expressed in more invasive and metastatic cancer tissues
[42]. The fact that MMP-2 is often associated with adjacent
normal tissues rather than the tumor cells themselves sug-
gests that neoplastic cells can use MMPs produced by normal
cells to facilitate their egress from the tumor mass and
Figure 2
The effects of MDA-MB-231 breast adenocarcinoma CM on MMP and TIMP activity from THP-1 monocytes. (a) Gelatin zymogram and (b) MMP-2 
immunoblot showing the upregulation of monocyte MMP-2 after exposure to MDA-MB-231 CM, and (c) a reverse zymogram to show that the activity 
of monocyte TIMP-2 was also upregulated upon exposure to MDA-MB-231 CM, although TIMP-1 activity remained the same upon treatment. Lanes 
1, 4, and 7 contain CM from THP-1 cells in serum-free media grown in the presence of 100 µl, 200 µl and 300 µl concentrated MDA-MB-231 CM, 
respectively. Lanes 2, 5, and 8 contain CM from THP-1 cells in serum-free media grown in the presence of 100 µl, 200 µl and 300 µl concentrated 
serum-free media, respectively. Lanes 3, 6, and 9 contain serum-free media with 100 µl, 200 µl and 300 µl, respectively, of MDA-MB-231 CM in the 
absence of THP-1 cells. These figures are representative of three independent experiments carried out in duplicate, each of which demonstrates 
similar results.
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cancer microenvironment may affect the monocyte MMP/TIMP
balance and, consequently, play a role in the ECM breakdown.
Considering the high concentration of infiltrating immune cells
in the breast cancer microenvironment, we examined whether
breast cancer cells modulate the reactivity of monocyte cells
by altering their production of MMPs and TIMPs. The data pre-
sented here suggest that monocyte-derived MMP, notably
MMP-2, may play an important role in invasive processes. Both
the protein levels and enzymatic activity of MMP-2 were ele-
vated in response to concentrated MCF-7 and MDA-MB-231
CM. TIMP-1 and TIMP-2 protein levels were both increased in
the CM treated cells. A study examining the effect of MCF-7
cells on human dermal fibroblasts found a similar observation,
in that the breast cancer cells augmented the production of
Figure 3
MCF-7 and MDA-MB-231 upregulation of TIMP-1 and TIMP-2 protein levels from THP-1 monocytesi l l f  -  t . Immunoblots representative of three independ-
ent experiments carried out in duplicate using monoclonal (a,b) TIMP-1 and (c,d) TIMP-2 antibodies to show an increased production of both pro-
teins by monocyte cells in response to MCF-7 and MDA-MB-231 CM. Lane 1 contains CM from THP-1 cells in serum-free media grown in the 
presence of 300 µl concentrated (a,c) MCF-7 CM and (b,d) MDA-MB-231 CM. Lane 2 contains CM from THP-1 cells in serum-free media grown in 
the presence of 300 µl concentrated serum-free media. Lane 3 contains serum-free media with 300 µl of (a,c) MCF-7 CM and (b,d) MDA-MB-231 
CM in the absence of THP-1 cells. Lane 4 contains unconcentrated (a) MCF-7 and (b,d) MDA-MB-231 CM.
Figure 4
The effects of monocyte cells and CM on the invasive potential of breast adenocarcinoma cells. Graphs showing an increase in the number of (a) 
MCF-7 and (b) MDA-MB-231 cells that migrated through matrigel-coated membranes in response to monocyte cell CM. The following conditions 
were used in the lower chamber: 1, serum-free media; 2, 10% FBS in serum-free media; 3, THP-1 cell-conditioned media; 4, (a) 5 × 104 MCF-7 
cells, (b) 5 × 104 MDA-MB-231 cells; 5, 5 × 104 THP-1 cells; 6, (a) 10 × 104 MCF-7 cells, (b) 10 × 104 MDA-MB-231 cells; 7, 10 × 104 THP-1 
cells. *p < 0.05 compared to condition 2; **p < 0.05 compared to condition 4; ***p < 0.05 compared to condition 6. The values are the means of 
three experiments and the error bars are the standard error of the mean.
Available online http://breast-cancer-research.com/content/7/5/R661
R667proMMP-1, -2, and -3 as well as TIMP-1 by fibroblast cells
[45]. In addition, others have shown that contact between
MDA-MB-231 cells and bone marrow derived fibroblasts
resulted in an increase in the concentration of MMP-2 in the
culture supernatant [46]. These findings are consistent with
the observation that fibroblast cells promote tumor progres-
sion in animal models through their production of MMPs [47-
49] and the findings emphasize the importance of tumor-host
interactions during cancer progression. A recent study by Blot
and colleagues [50] provides additional evidence on the role
of monocytes in breast cancer. The authors cultured periph-
eral monocytes with MDA-MB-231 breast cancer cells and
noticed an increase in MMP-9 expression [50]. Thus, the abil-
ity of MCF-7 and MDA-MB-231 cells to augment the produc-
tion of MMPs in surrounding normal cells is likely one of the
important properties for cell invasion and metastasis by these
two breast cancer cell lines. However, since the THP-1 mono-
cyte cell line differs in many respects from TAMs, further study
is needed to assess the in vivo activities of monocyte cells and
to determine if MMP-2 is upregulated by monocytes in the
breast cancer microenvironment in vivo.
Collectively, these findings shed new light on the role of tumor-
associated monocytes in the regulation of breast tumor devel-
opment, invasion and metastasis. Increased MMP production
has been shown to break down the basement membrane
around pre-invasive tumors, thereby enhancing the ability of
tumor cells to escape into the surrounding stroma. Thus, it is
becoming apparent that stromal cells in the tumor microenvi-
ronment play an important role in allowing the tumor to express
its full neoplastic phenotype. Consequently, further studies
could reveal many new pathophysiological implications of
MMPs in their regulation of immune cells, cytokine and chem-
okine networks, and matrix proteolysis during the metastatic
process.
Conclusion
This study supports the hypothesis that tumor cell-host stro-
mal cell interactions play a critical role in the proteolytic cas-
cade required for tumor progression. Here we have focussed
on one type of solid tumor, carcinoma of the breast. Monocyte
MMP-2 enzymatic activity and MMP-2 as well as TIMP-1 and
TIMP-2 protein levels were increased in response to soluble
factors from MCF-7 and MDA-MB-231 breast cancer cells.
Furthermore, the breast cancer cells displayed significantly
enhanced in vitro invasion in response to monocyte CM.
These data provide evidence for a potentially important
function of monocytes in the modulation of MMPs and degra-
dation of connective tissue in neoplastic disease.
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